 Adaptimmune Therapeutics plc NASDAQ: ADAP has reported first preclinical data from its HiT targeting mesothelin a tumor-associated antigen, being co-developed with Astellas Pharma OTCMKTS: ALPMF The data were presented at the American Society for Cell and Gene Therapy ASGCT meeting. 